Furthermore, mTORC1 and SREBP-1c activity are known to remain somewhat independent of Akt (possibly regulated by IRS or independent of the canonical pathway) [173], which could contribute to the development of hepatic steatosis. Here, AKT1 is linked to fatty liver disease.